Key result
Osteopontin protein was expressed in 34.2% of adrenocortical carcinomas (25/73) but absent in all adenomas (p=0.0022), identifying it as a potential diagnostic biomarker.
Why the study?
Molecular mechanisms of adrenocortical carcinoma development are incompletely defined, though deregulation of cell-to-extracellular matrix interactions and angiogenesis are implicated in the malignant phenotype.
Observational (n=105)
Absolute Event Rate: 34.2% vs 0%
p-value: p=0.0022
Osteopontin and HAS-1 are identified as potential diagnostic and prognostic biomarkers in adrenal cortical tumors.
May distinguish adrenal carcinomas from adenomas; leaves open validation as a diagnostic biomarker before clinical use.
The molecular mechanisms of adrenocortical carcinoma development are incompletely defined. De-regulation of cellular-to-extracellular matrix interactions and angiogenesis appear among mechanisms associated to the malignant phenotype. Our aim was to investigate, employing PCR-based array profiling, 157 molecules involved in cell-to-matrix interactions and angiogenesis in a frozen series of 6 benign and 6 malignant adrenocortical neoplasms, to identify novel pathogenetic markers. In 14 genes, a significant dysregulation was detected in adrenocortical carcinomas as compared to adenomas, most of them being downregulated. Three exceptions—hyaluronan synthase 1 (HAS-1), laminin α3 and osteopontin genes—demonstrated an increased expression in adrenocortical carcinomas of 4.46, 4.23 and 20.32-fold, respectively, and were validated by immunohistochemistry on a series of paraffin-embedded tissues, including 20 adenomas and 73 carcinomas. Osteopontin protein, absent in all adenomas, was expressed in a carcinoma subset (25/73) (p = 0.0022). Laminin α3 and HAS-1 were mostly expressed in smooth muscle and endothelial cells of the vascular network of both benign and malignant adrenocortical tumors. HAS-1 was also detected in tumor cells, with a more intense pattern in carcinomas. In this group, strong expression was significantly associated with more favorable clinicopathological features. These data demonstrate that cell-to-matrix interactions are specifically altered in adrenocortical carcinoma and identify osteopontin and HAS-1 as novel potential diagnostic and prognostic biomarkers, respectively, in adrenal cortical tumors.
No takes yet. Share an insight, caveat, or question.
Volante et al. (2021) conducted an observational in Adrenocortical tumors (n=105). Adrenocortical carcinoma vs. Adrenocortical adenoma was evaluated on Osteopontin protein expression (p=0.0022). Osteopontin protein was expressed in 34.2% of adrenocortical carcinomas (25/73) but absent in all adenomas (p=0.0022), identifying it as a potential diagnostic biomarker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: